Rapport Therapeutics annual ebitda
2023
2024
2025
Rapport Therapeutics EBITDA Growth & History (RAPP)
Rapport Therapeutics's calculated EBITDA was −$124.1M for fiscal 2025.
View full Rapport Therapeutics company overviewRapport Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$124.1M | −$41.9M | — |
| 2024 | 2024-12-31 | −$82.2M | −$46.1M | — |
| 2023 | 2023-12-31 | −$36.1M | — | — |
Rapport Therapeutics quarterly ebitda
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$60.6M | −$31.4M | — |
| Q1 2026 | 2026-03-31 | −$24.0M | $2.9M | — |
| Q4 2025 | 2025-12-31 | −$38.2M | −$15.0M | — |
| Q3 2025 | 2025-09-30 | −$29.7M | −$8.3M | — |
| Q2 2025 | 2025-06-30 | −$29.2M | −$8.7M | — |
| Q1 2025 | 2025-03-31 | −$26.9M | −$9.9M | — |
| Q4 2024 | 2024-12-31 | −$23.3M | — | — |
| Q3 2024 | 2024-09-30 | −$21.4M | −$11.9M | — |
| Q2 2024 | 2024-06-30 | −$20.6M | — | — |
| Q1 2024 | 2024-03-31 | −$16.9M | — | — |
| Q3 2023 | 2023-09-30 | −$9.5M | — | — |
Rapport Therapeutics ebitda trends
Between the periods ended 2023-12-31 and 2025-12-31, Rapport Therapeutics's ebitda decreased from −$36.1M to −$124.1M, a change of −$88.0M. The latest reported quarter, Q2 2026, shows −$60.6M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Rapport Therapeutics source filings ↗Community posts
Rapport’s bipolar-mania study meets its primary endpoint in Phase 2
Rapport Therapeutics ($RAPP) reported positive topline results from a randomized, double-blind Phase 2 trial of RAP-219 in 253 adults with acute mania associated with bipolar I disorder. After three weeks, the treatment group improved by 15 ...
